These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35628945)

  • 21. Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.
    Araki E; Yamashita S; Arai H; Yokote K; Satoh J; Inoguchi T; Nakamura J; Maegawa H; Yoshioka N; Tanizawa Y; Watada H; Suganami H; Ishibashi S
    Diabetes Care; 2018 Mar; 41(3):538-546. PubMed ID: 29298800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease.
    Ikeda S; Sugihara T; Hoshino Y; Matsuki Y; Nagahara T; Okano JI; Kitao S; Fujioka Y; Yamamoto K; Isomoto H
    Yonago Acta Med; 2020 Aug; 63(3):188-197. PubMed ID: 32884438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Case report: a potential modulation of coronary atheroma by lowering triglyceride-rich lipoproteins with pemafibrate: insights from serial near-infrared spectroscopy imaging.
    Murata Y; Kataoka Y; Asaumi Y; Noguchi T
    Cardiovasc Diagn Ther; 2023 Feb; 13(1):100-108. PubMed ID: 36864976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pemafibrate, A Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Reduces Plasma Eicosanoid Levels and Ameliorates Endothelial Dysfunction in Diabetic Mice.
    Suto K; Fukuda D; Shinohara M; Ganbaatar B; Yagi S; Kusunose K; Yamada H; Soeki T; Hirata KI; Sata M
    J Atheroscler Thromb; 2021 Dec; 28(12):1349-1360. PubMed ID: 33775978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
    Yokote K; Yamashita S; Arai H; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
    Cardiovasc Diabetol; 2021 May; 20(1):96. PubMed ID: 33947390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance.
    Matsuba I; Matsuba R; Ishibashi S; Yamashita S; Arai H; Yokote K; Suganami H; Araki E
    J Diabetes Investig; 2018 Nov; 9(6):1323-1332. PubMed ID: 29603684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate.
    Yamashita S; Okazaki M; Okada T; Masuda D; Yokote K; Arai H; Araki E; Ishibashi S
    J Atheroscler Thromb; 2021 Sep; 28(9):974-996. PubMed ID: 33536398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
    Arai H; Yamashita S; Yokote K; Araki E; Suganami H; Ishibashi S;
    J Atheroscler Thromb; 2018 Jun; 25(6):521-538. PubMed ID: 29628483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMα), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia.
    Tanaka A; Nakamura T; Sato E; Chihara A; Node K
    CEN Case Rep; 2020 May; 9(2):141-146. PubMed ID: 31950425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
    Fruchart JC; Hermans MP; Fruchart-Najib J
    Curr Atheroscler Rep; 2020 Jul; 22(8):43. PubMed ID: 32671476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: A single-arm, pilot study.
    Seko Y; Yamaguchi K; Umemura A; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Moriguchi M; Okanoue T; Itoh Y
    Hepatol Res; 2020 Dec; 50(12):1328-1336. PubMed ID: 32926754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study.
    Komiya I; Yamamoto A; Sunakawa S; Wakugami T
    Lipids Health Dis; 2021 Feb; 20(1):17. PubMed ID: 33610176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.
    Ishibashi S; Yamashita S; Arai H; Araki E; Yokote K; Suganami H; Fruchart JC; Kodama T;
    Atherosclerosis; 2016 Jun; 249():36-43. PubMed ID: 27062408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Effects of Pemafibrate in Japanese Patients with Type 2 Diabetes Receiving HMG-CoA Reductase Inhibitors.
    Kusunoki M; Sakazaki T; Tsutsumi K; Miyata T; Oshida Y
    Endocr Metab Immune Disord Drug Targets; 2021; 21(5):919-924. PubMed ID: 32819242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of fibric acid derivatives in the management of risk factors for coronary heart disease.
    Després JP; Lemieux I; Robins SJ
    Drugs; 2004; 64(19):2177-98. PubMed ID: 15456334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.
    Nakajima A; Eguchi Y; Yoneda M; Imajo K; Tamaki N; Suganami H; Nojima T; Tanigawa R; Iizuka M; Iida Y; Loomba R
    Aliment Pharmacol Ther; 2021 Nov; 54(10):1263-1277. PubMed ID: 34528723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients.
    Sugimoto R; Iwasa M; Eguchi A; Tamai Y; Shigefuku R; Fujiwara N; Tanaka H; Kobayashi Y; Ikoma J; Kaito M; Nakagawa H
    Front Med (Lausanne); 2023; 10():1073025. PubMed ID: 36824614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study.
    Araki E; Yamashita S; Arai H; Yokote K; Satoh J; Inoguchi T; Nakamura J; Maegawa H; Yoshioka N; Tanizawa Y; Watada H; Suganami H; Ishibashi S
    Diabetes Obes Metab; 2019 Jul; 21(7):1737-1744. PubMed ID: 30830727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibrates, dyslipoproteinaemia and cardiovascular disease.
    Watts GF; Dimmitt SB
    Curr Opin Lipidol; 1999 Dec; 10(6):561-74. PubMed ID: 10680050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease.
    Shinozaki S; Tahara T; Lefor AK; Ogura M
    Clin Exp Hepatol; 2020 Sep; 6(3):270-274. PubMed ID: 33145434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.